Zosano Appoints New Chief Financial Officer
16 10월 2018 - 9:30PM
Seasoned financial and operational executive
further strengthens management team
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
“Company”), a clinical-stage biopharmaceutical company developing
and commercializing therapies that deliver rapid systemic
absorption by leveraging its novel and proprietary technology,
Adhesive Dermally-Applied Microneedle System (“ADAM™”), today
announced the appointment of Greg Kitchener to the position of
chief financial officer (CFO).
“We are pleased to announce the addition of Greg Kitchener to
Zosano as our new CFO,” said John Walker, chief executive officer
and chairman of the board at Zosano. “Greg joins us at a pivotal
time in the advancement of our clinical pipeline. Our lead program,
M207, is moving towards an NDA filing with the FDA and we plan on
adding additional assets to our portfolio over the next year.”
“Greg has served in a variety of senior leadership roles at
several publicly traded companies, during which he has supported
growth, improved operations and built successful teams. We are
confident that Greg will help Zosano accomplish our future goals
and that his breadth of financial and operational experience will
help transition the Company to its next phase as a commercial
enterprise,” concluded Mr. Walker.
Mr. Kitchener has over 20 years of broad financial leadership
experience in financial planning and analysis, treasury, accounting
and investor relations. Prior to joining Zosano, Mr. Kitchener
served as CFO and executive vice president at BioPharmX Corporation
(NYSE American: BPMX). He was also previously a vice president of
finance at Cepheid (acquired by Danaher Corporation) and a director
of corporate planning at Synopsys, Inc. He received his
undergraduate degree from the University of California, Santa Cruz
and earned his MBA from Cornell University.
About M207M207 is Zosano’s proprietary
formulation of zolmitriptan delivered utilizing its proprietary
ADAM technology. Zosano's ADAM technology consists of titanium
microprojections (microneedles) coated with drug, and in the case
of M207, its formulation of zolmitriptan. The drug-coated
microneedles penetrate into the epidermis and dermis, where the
drug is dissolved and enters into the bloodstream. In February
2017, the Company announced statistically significant results from
the ZOTRIP pivotal study, which demonstrated that the 3.8mg dose of
M207 met both co-primary endpoints, achieving pain freedom and most
bothersome symptom freedom at 2 hours. In November 2017, the
Company announced the initiation of its long-term safety study
evaluating M207 and expects to file a New Drug Application for M207
in the fourth quarter of 2019.
Forward-Looking StatementsThis press release
contains forward-looking statements regarding the timing of
expected clinical development milestones and other future events
and expectations. Readers are urged to consider statements that
include the words "may," "will," "would," "could," "should,"
"might," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," "unaudited," "approximately" or the
negative of those words or other comparable words to be uncertain
and forward-looking. These statements are subject to risks and
uncertainties that are difficult to predict and actual outcomes may
differ materially. These include risks and uncertainties, without
limitation, associated with the process of discovering, developing
and commercializing products that are safe and effective for use as
human therapeutics, risks inherent in the effort to build a
business around such products and other risks and uncertainties
described under the heading "Risk Factors" in the Company's most
recent annual report on Form 10-K. Although we believe that the
expectations reflected in these forward-looking statements are
reasonable, we cannot in any way guarantee that the future results,
level of activity, performance or events and circumstances
reflected in forward-looking statements will be achieved or occur.
All forward-looking statements are based on information currently
available to Zosano and Zosano assumes no obligation to update any
such forward-looking statements.
Zosano Contact:John WalkerChief Executive
Officer and Chairman of the Board510-745-1200
Media Contact:Sara ZelkovicLifeSci Public
Relationssara@lifescipublicrelations.com646-876-4933
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024